Wegovy carries an FDA indication for ages 12 and older, but approval for a specific 16-year-old requires physician authorization and documented medical necessity
& Taylor, I
Unlike earlier treatments, it acts as a "Dual Agonist," targeting two separate hormone receptors to maximize metabolic efficiency and appetite control
What we do at this stage At the initial application stage, our role is to make sure the application is complete and the medical record is fully developed before DDS reviews it
In conclusion we can assess that glutathione metabolism is differently affected in the two resistant strains to the examined drugs and that in CO23RFLC, glutathione system is an important part of the overall organization of this cells for resistance
Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R (2017) Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata